B. Riley Wealth Advisors Inc. Sells 926 Shares of Danaher Co. (NYSE:DHR)

B. Riley Wealth Advisors Inc. trimmed its holdings in shares of Danaher Co. (NYSE:DHR) by 8.1% during the first quarter, HoldingsChannel reports. The firm owned 10,508 shares of the conglomerate’s stock after selling 926 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in Danaher were worth $2,607,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in DHR. Cape Investment Advisory Inc. purchased a new position in Danaher during the 4th quarter valued at about $25,000. Tsfg LLC grew its holdings in Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after buying an additional 88 shares in the last quarter. Wetzel Investment Advisors Inc. purchased a new position in shares of Danaher during the fourth quarter worth about $29,000. Redmont Wealth Advisors LLC purchased a new position in shares of Danaher during the first quarter worth about $30,000. Finally, Rakuten Securities Inc. purchased a new position in shares of Danaher during the fourth quarter worth about $36,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In related news, CFO Matthew Mcgrew sold 46,377 shares of Danaher stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at approximately $7,441,441.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Danaher news, CEO Rainer Blair sold 19,085 shares of Danaher stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $255.00, for a total value of $4,866,675.00. Following the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at approximately $29,578,725. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Matthew Mcgrew sold 46,377 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $253.05, for a total value of $11,735,699.85. Following the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $7,441,441.35. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 84,067 shares of company stock valued at $21,630,236. 11.10% of the stock is owned by company insiders.

Danaher Stock Up 0.7 %

DHR stock opened at $277.08 on Thursday. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $280.26. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The stock has a market cap of $200.11 billion, a P/E ratio of 46.96, a PEG ratio of 4.53 and a beta of 0.83. The business’s 50-day moving average price is $255.62 and its 200-day moving average price is $250.20.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the firm earned $2.05 EPS. The business’s quarterly revenue was down 2.9% on a year-over-year basis. On average, equities research analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, July 26th. Investors of record on Friday, June 28th were paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.39%. The ex-dividend date was Friday, June 28th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Analysts Set New Price Targets

Several research analysts have recently commented on DHR shares. Bank of America boosted their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. The Goldman Sachs Group boosted their target price on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. SVB Leerink boosted their price objective on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Stifel Nicolaus boosted their price objective on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Finally, Royal Bank of Canada boosted their price objective on Danaher from $297.00 to $300.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Six equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $276.88.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.